Draft PRODUCT INFORMATION - Medsafe
140416 NEXAVAR data sheet Page 1 of 25 Data Sheet . NEXAVAR ® Sorafenib tosylate Tablets, film-coated 200 mg . Name of the Medicine . NEXAVAR is a multikinase inhibitor targeting several serine/threonine and receptor
Download Draft PRODUCT INFORMATION - Medsafe
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
EASL–EORTC Clinical Practice Guidelines: Management of ...
www.easl.euEASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver⇑, European Organisation for Research and Treatment of Cancer
JSTHAECRG-2011-01 (HCC-CDDP+Lipiodol-PⅡ) 進行肝細胞癌 …
thae.kenkyuukai.jpJSTHAECRG (Japan Society of Transcatheter Hepatic Arterial Embolization Clinical Reserch Group) JSTHAECRG-2011-01 (HCC-CDDP+Lipiodol-PⅡ) 進行肝細胞癌に対する動注用シスプラチン・リピオドール懸 …
第6 章 肝動脈 化学 塞栓療法 TA(C)E CQ37
www.nihon-kangan.jp第6 章 肝動脈(化学)塞栓療法TA(C)E 140 CQ37 TACE/TAE はどのような患者に行うべきか？ 推 奨 腫瘍個数4 個以上，Child 分類のA～B，performance status 0～2 のBCLC Stage B
第5章 肝動脈化学塞栓療法 TACE - jsh.or.jp
www.jsh.or.jp第5章 肝動脈化学塞栓療法TACE 139 （advanced stage）， performance status 1～2，門脈浸潤（－），N1（－），M1（－）と述
Carcinoma hepatocelular: diagno´stico, estadificacio´n y ...
webcir.orgcausarı´a una elevada irradiacio´n de los pacientes y serı´a caro a nivel coste/beneficio18.La RM tiene una gran sensibilidad y especificidad en el diagno´stico del CHC de
第5 章 肝動脈化学塞栓療法（TACE - jsh.or.jp
www.jsh.or.jp第5 章 肝動脈化学塞栓療法（ tace ） はじめに いわゆる典型的な多血性肝細胞癌は動脈血で栄養されている。
CLAIMS AGAINST THIRD PARTIES Jeremy Bamford & Simon ...
www.guildhallchambers.co.uk1 CLAIMS AGAINST THIRD PARTIES Jeremy Bamford & Simon Passfield, Guildhall Chambers A. Introduction 1. This paper supports and provides the references for the Wonderland Ltd case study1 which will be considered during the seminar.